CPNs in COVID-19 diagnostics development
We have launched a joint venture with MIP Diagnostics Ltd, a company who manufacture nanoMIPs or ‘plastic antibodies’. The collaborative project will focus on the development of a COVID-19 (or SARS-Cov-2) antigen reagent for assays, a point of care, lateral flow Rapid Diagnostic Test (RDT) and an ‘ELISA’ type assay for high throughput screening (HTS) or mass testing, a complimentary alternative to PCR.
The unique stable properties of both Stream’s and MIP’s novel technologies allows for fast development of an extremely sensitive and stable detection platform for the virus. The lateral flow project aims to reduce the diagnosis time to just 10 minutes, while the ELISA assay would enable a different detection system common in nearly all labs to be utilised alongside PCR, dramatically increasing capability. Read our latest press release here to learn more about our collaboration with MIP Diagnostics Ltd.
CPNs in your own research or diagnostics development
CPNs are significantly brighter than Alexa dyes and europium chelates, dramatically improving diagnostic test sensitivity, and allowing earlier and more reliable detection. CPNs are also incredibly stable, resistant to photobleaching and resistant to extremities of temperature and pH. The enhanced stability of CPNs facilitates their use in challenging environments and improves diagnostic methods that are currently limited by their detection sensitivity. This enables them to become reliable and trusted tools to combat infection.
When used in binding assays, the magnetic properties of CPNs can be utilised to increase the assay signal and detection window significantly, allowing greater sensitivity in assays and therefore earlier detection of disease biomarkers.
If you are interested in harnessing the superior capabilities of CPNs in your own research or diagnostics development, click here to learn more about our bespoke antibody conjugation service.